MedTrace Logo

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

NCT00322452 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1329

Last updated 2013-11-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority.

Conditions

Interventions

DRUG

Gefitinib

oral tablet

DRUG

Carboplatin

IV

DRUG

Paclitaxel

IV

Sponsors & Collaborators

Principal Investigators

  • Alison Armour, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-04-30
Completion
2010-06-30

Countries

  • China
  • Hong Kong
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00322452 on ClinicalTrials.gov